+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase Not Applicable
Age: 18Years - 80Years
All Genders
ID07064109

Study of Colchicine Treatment Effects on Inflammation in Adults with Acute Coronary Syndrome Using Multi-omics Analysis and Model Development

Led by Shanghai Tongji Hospital, Tongji University School of Medicine · Updated on 2025-09-15

380

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying patients with Acute Coronary Syndrome ACS to understand how colchicine, an anti-inflammatory drug, works in treating this condition. This prospective cohort study aims to explore the biological mechanisms behind colchicine therapy and to develop a model predicting which patients might benefit from this treatment. The study is led by Shanghai Tongji Hospital, Tongji University School of Medicine. Participants are randomly assigned to one of two groups one group receives low-dose colchicine 0.5 mg orally once daily alongside standardized treatment for ACS, while the other group receives only the standardized treatment. The study evaluates the effects of adding colchicine over time, focusing on the drugs anti-inflammatory benefits in patients with ACS. During the study, participants will be monitored for response to treatment at 6 months and for improvements in coronary artery function at 1 year after enrollment. Researchers will also track the incidence of major adverse cardiovascular events MACE within one year. The study runs for up to 2 years, offering detailed assessments of patient outcomes and treatment effects.

CONDITIONS

Brief Title

Multi-omics Characterization and Model Construction of Colchicine Anti-inflammatory Therapy Efficacy in ACS Patients

Research Team

X

Xuebo Liu

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here